This was a single-center, 2-arm, parallel-group, prospective, pilot randomized controlled trial. Patients were randomized 1:1 to the intervention and control groups using a computer-generated randomization list. Due to the nature of the study design, neither program implementers nor patients could be blinded to the intervention. However, the investigators performing the outcome assessments and data analysis were blinded to the group allocation.

Both the intervention and control groups were administered 2 surveys, one 30 minutes before ablation and one within 30 minutes after ablation, to assess pain intensity, fatigue, and anxiety using specific paper questionnaires. Demographic information and characteristics of participants were collected at baseline. The study staff recorded patients' hemodynamic parameters (heart rate, blood pressure, and peripheral oxygen saturation [SpO₂]), spontaneously reported pain, the doses of sedative drugs used, and adverse events during ablation.

The primary outcomes were pain and anxiety levels during ablation and fatigue severity after ablation. The intensity of pain was measured using the numeric rating scale, with scores that ranged from 0 (no pain) to 10 (the worst possible pain) [32,33]. The State Anxiety Inventory (A-State) is a subscale of the State-Trait Anxiety Inventory [34], which is mainly used to assess the anxiety state in a specific situation. The A-State score was used in this study to explore the anxiety level of patients during ablation. We evaluated the patients' fatigue after ablation using the Brief Fatigue Inventory (BFI) [35], a 10-item validated scale. A higher score indicates a greater level of fatigue.

Secondary outcomes included mean heart rate, blood pressure, and SpO₂ during ablation. Adverse events were defined as excessive fluctuations in blood pressure (fluctuations of >50 mm Hg in systolic blood pressure), nausea and vomiting, and vasovagal reaction. The study staff also recorded the number of times of spontaneously reported pain and the doses of sedative drugs used during ablation.

Statistical analysis was performed using SPSS (version 22.0; IBM Corp) and based on the intention-to-treat principle with a 2-sided significance level of .05. Data were analyzed using descriptive statistics and checked for the normality of their distribution. Descriptive continuous variables are presented as mean (SD) values and categorical variables as frequency and percentage values. Differences between study groups were analyzed using an independent 2-sample t test for numerical variables and the Mann-Whitney U test, chi-square test, or the Fisher exact test for categorical variables.

This study was conducted at the cardiac catheterization laboratory of the First Affiliated Hospital of Nanjing Medical University, Nanjing, China, from April to September 2022. All study patients provided oral or written informed consent. This study was approved by the ethics committee of the First Affiliated Hospital of Nanjing Medical University (2022-SR-086) and registered at ClinicalTrials.gov (NCT05306015). Procedures were conducted in accordance with the tenets of the Declaration of Helsinki.

A total of 84 patients (42 patients each in the intervention and control groups) were enrolled and completed baseline measures in this study. A total of 4 patients (2 each from the intervention and control groups) were excluded from the study. Figure 2 shows the CONSORT (Consolidated Standards of Reporting Trials) diagram for this clinical trial.

No significant differences were found between the intervention group and the control group in baseline characteristics (Table 1). Neither group had previous experience with practicing mindfulness meditation.

We found no significant difference in the baseline pain, anxiety, and fatigue scores between the intervention and control groups (Table 2). After the intervention, compared to the control group, there were significant differences in numeric rating scale (mean 4.6, SD 1.7 [intervention group] vs mean 5.7, SD 2.1 [control group]; P=.008) and A-State (mean 36.7, SD 5.5 vs mean 42.3, SD 7.2; P<.001) scores after ablation. The BFI score after ablation was significantly lower in the intervention group than in the control group (mean 3.4, SD 2.3 vs mean 4.7, SD 2.2; P=.01).

Between the intervention and control groups in ablation, there were no significant differences in the mean heart rate (mean 87.4, SD 15.7 [intervention group] vs mean 91.1, SD 16.4 [control group] beats per minute; P=.31), systolic blood pressure (mean 127.2, SD 15.7 vs mean 131.9, SD 17.4 mm Hg; P=.21), diastolic blood pressure (mean 81.1, SD 10.5 vs mean 82.7, SD 9.6 mm Hg; P=.49), and SpO₂ (mean 98.4%, SD 1.3% vs mean 98.5%, SD 1.2%; P=.71; Figure 3).

There were no significant differences in parecoxib and dexmedetomidine use between the intervention and control groups during ablation. The intervention group had significantly decreased fentanyl use compared to the control group (P=.003; Table 3). Additionally, patients in the intervention group reported significantly fewer times of pain than those in the control group during ablation (P<.001). The incidence of adverse events in the intervention group was lower than that in the control group, but the difference did not reach statistical significance (P=.15).

The purpose of this study was to evaluate the effectiveness of a novel BCI-based mindfulness meditation app for patients with AF to improve their physical and psychological status in RFCA. The selected app provides EEG feedback for mindfulness meditation, which may help patients relax and reduce unpleasant experiences without interfering with the ablation process. The key findings showed significantly lower pain, anxiety, and fatigue scores in the intervention group than among those receiving conventional care. No significant differences were found in the mean heart rate, blood pressure, or SpO₂ between groups during RFCA. Additionally, the intervention group had a significant decrease in fentanyl use, while the differences in other sedative drugs were not significant. Although the incidence of adverse events was lower in the intervention group, the difference was not significant.

Mobile health, via wireless technologies such as smartphone apps and wearable devices, is currently used for patients with AF mostly for screening, management, and rehabilitation [36-39]. Numerous studies have investigated the impact of meditation on cardiac disease and suggest that it may offer potential benefits for cardiovascular health, including reducing blood pressure, improving psychological and physiological responses to stress, and possibly mitigating AF progression by modulating the autonomic nervous system [21,40]. Mobile app–based mindfulness meditation has the potential to serve as an adjunct to the RFCA procedure for patients with AF owing to its low risks, potential benefits, and relatively low cost. Nevertheless, it is essential to acknowledge the costs associated with using a commercialized app and headband device, along with the requirement for labor and its cost to monitor the app. Additionally, caution should be exercised in making claims about the low risk of this intervention, as it is based solely on the findings of this small pilot study. Further research is needed to explore the relationship between meditation and AF ablation. To our knowledge, this is the first study to assess the effectiveness of a mindfulness meditation app together with a BCI-based wearable device for patients with AF during RFCA. This study achieved promising results and indicated that this type of intervention could be easily integrated into the standard RFCA workflow.

It is well known that RFCA for AF can be accompanied by considerable pain and anxiety when conscious sedation is used, which, however, has potential side effects [15]. Anxiety is common in patients with AF [41]. Patients may experience pain and uncertainty for several hours during RFCA, which could amplify negative emotions such as anxiety and made them feel exhausted. Therefore, it is necessary to monitor and intervene in patients with AF’s anxiety during ablation procedures [16]. Previous studies have indicated that apps based on nonpharmacological interventions could effectively reduce the fatigue, anxiety, pain, and the use of sedative drugs in invasive medical treatment [42-44]. Nørgaard et al [45] examined the effects of visualization together with usual pain medication in comparison with conventional care among patients with AF undergoing RFCA, and found significant reductions in the perception of pain and anxiety, as well as the doses of analgesics used in the intervention group [46]. Wearable devices are drastically changing medical practices nowadays. Roxburgh et al [47] implemented a virtual reality headset for patients with AF undergoing cryoballoon ablation under conscious sedation and found that the virtual reality group had a significantly lower perceived pain score and higher comfort score. In recent years, there has been a growing body of literature examining the effects of mindfulness training supported by EEG feedback. Crivelli et al [48] investigated the potential benefits of EEG-based brain-sensing device–supported mindfulness practices in individuals with mild stress levels and found a significant reduction in stress and anxiety. Similarly, Balconi et al [49] used mindfulness exercises in combination with wearable EEG information sensor devices to explore the effect of reducing overall stress levels in healthy individuals and found significant improvements in physiological (heart rate and variability) and subjective markers of stress (perceived stress, anxiety, and mood states). These findings are in line with those of this study, suggesting that EEG feedback may facilitate meditation by providing real-time information to aid users in achieving a mindfulness state. In our study, we assessed the effectiveness of an intervention based on a mindfulness meditation app combined with a BCI-based wearable device, which provides meditation guidance with synchronous EEG feedback to patients. This intervention has a minimal learning curve without requiring specialist training and provides personalized feedback, which may enhance patient engagement and adherence [50]. The potential mechanisms underlying pain, anxiety, and fatigue relief through mindfulness meditation are likely linked with the ability of meditation to change the activity of the insula, somatosensory cortex, anterior cingulate cortex, and prefrontal cortex. These changes may reduce patients' attention, memory, and perception of physical and psychological discomfort [51,52].

When patients experience physical and mental discomfort in RFCA, the levels of catecholamines, adrenocorticotropic hormone, prolactin, cortisol, and prostaglandins in their blood may increase [53], which could result in unstable hemodynamic parameters (heart rate, blood pressure, and SpO₂) [54] and, thereby, affect the performance of procedures and patient safety. Previous studies have indicated that nonpharmacological interventions could effectively stabilize hemodynamic parameters in invasive operative procedures [42,55]. In this study, however, the between-group differences in mean heart rate, blood pressure, or SpO₂ during RFCA did not reach statistical significance. The observed discrepancy between objective and subjective outcomes may be attributed to various factors. One possible explanation is that blood pressure changes induced by meditation through the autonomic nervous system may be a long-term process [21]. Furthermore, the timing of data collection may have influenced the findings, as objective measures were collected during the intervention, whereas subjective data were gathered through self-reports post intervention. It is worth noting that patients with AF frequently experience AF episodes during RFCA procedures, which may lead to variations in heart rate and blood pressure levels and contribute to the lack of significant differences between the groups. Additional research with larger sample sizes may help elucidate the potential impact of the intervention on these objective parameters. Although there was no significant difference, the incidence of adverse events was lower in the intervention group. This indicates a possibility for the potential protective effects of our intervention during RFCA, which merit further investigations.

A strength of this study is that it is the first randomized controlled trial, to our knowledge, to explore the effectiveness of a mindfulness meditation app together with a BCI-based wearable device among patients with AF during RFCA, which adds to the evidence base in the areas of meditation and mobile health. This study was designed rigorously. We provided the same care protocol and implemented the use of wearable devices for both groups, and recorded the time, energy, and temperature of ablation to ensure comparable conditions. In addition, this study was performed in a pragmatic setting and no maximum age for participation was stated, which adds to the generalizability of our findings.

This study also has some limitations. First, it was not a double-blind trial. Neither study staff nor patients were blinded to the intervention due to the nature of the study design. However, the data analysts were masked to group allocation. Additionally, meditation practice is a long-term process. Even with the help of apps and wearable devices, it takes time to master meditation techniques to reach a meditative state faster. At least one preoperative practice session could be added to the protocol for the intervention group; however, this might affect the comparability of the baseline measures. Lastly, this is a single-center study, thus limiting the generalizability of our findings.

In conclusion, this study shows that BCI-based app–delivered mindfulness meditation significantly relieved pain, anxiety, fatigue, and may reduce the doses of sedative medication used during RFCA for AF. Although no significant differences in hemodynamic parameters and the incidence of adverse events were observed, there was a decrease in the incidence of adverse events in the intervention group. Smartphone apps and wearable devices could serve as feasible and promising adjuncts to improve patients with AF’s experience in RFCA.